New AI solution being tested at Umeå vaccine facility

A new AI solution for sustainable production is to be tested at Diamyd Medical’s vaccine manufacturing facility in Umeå. It is hoped, once the solution has been refined, that it can be introduced in companies throughout Sweden.
“This represents a unique opportunity that we do not see that often in Sweden. We are happy to be working with recognised experts in both AI and sustainable production”, says Ulf Hannelius, CEO of Diamyd Medical.

Read more

Diamyd Medical moves pharmaceutical production from USA to Umeå – hires

A recruitment drive is underway at Diamyd Medical’s new vaccine facility in Umeå after the company announced it is moving production of the GAD65 protein, the active substance in the diabetes vaccine Diamyd, from abroad to Sweden.
“This move gives us greater control and more knowledge about our study drug. Personally it feels fantastic to be involved in building a vaccine facility from the ground up”, says Maja Johansson, Site Manager in Umeå.

Read more

Key appointments being made at new diabetes vaccine facility in Umeå

Construction of Diamyd Medical’s new vaccine manufacturing unit in Umeå is now underway, with a number of key roles being actively recruited to help staff the new facility. Newly-appointed site manager Maja Johansson is responsible for establishing the process for the production of GAD, the active substance in the study drug Diamyd.

Read more